Opthea (OPT) Competitors $3.22 -0.05 (-1.53%) (As of 03:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends OPT vs. KURA, IMNM, TYRA, ERAS, CRON, EOLS, DNTH, RAPP, OCS, and AUTLShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Kura Oncology (KURA), Immunome (IMNM), Tyra Biosciences (TYRA), Erasca (ERAS), Cronos Group (CRON), Evolus (EOLS), Dianthus Therapeutics (DNTH), Rapport Therapeutics (RAPP), Oculis (OCS), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Kura Oncology Immunome Tyra Biosciences Erasca Cronos Group Evolus Dianthus Therapeutics Rapport Therapeutics Oculis Autolus Therapeutics Opthea (NASDAQ:OPT) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking. Is OPT or KURA more profitable? Opthea's return on equity of 0.00% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Kura Oncology N/A -44.09%-39.57% Does the media favor OPT or KURA? In the previous week, Opthea had 1 more articles in the media than Kura Oncology. MarketBeat recorded 2 mentions for Opthea and 1 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.96 beat Opthea's score of -0.03 indicating that Kura Oncology is being referred to more favorably in the news media. Company Overall Sentiment Opthea Neutral Kura Oncology Positive Which has preferable earnings and valuation, OPT or KURA? Kura Oncology has lower revenue, but higher earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$124.67K1,529.36-$220.24MN/AN/AKura OncologyN/AN/A-$152.63M-$2.36-4.13 Which has more risk and volatility, OPT or KURA? Opthea has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Do institutionals & insiders hold more shares of OPT or KURA? 56.0% of Opthea shares are held by institutional investors. 3.2% of Opthea shares are held by insiders. Comparatively, 5.5% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate OPT or KURA? Opthea presently has a consensus price target of $12.00, indicating a potential upside of 267.53%. Kura Oncology has a consensus price target of $29.38, indicating a potential upside of 201.59%. Given Opthea's higher probable upside, analysts clearly believe Opthea is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Kura Oncology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in OPT or KURA? Kura Oncology received 409 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 69.56% of users gave Kura Oncology an outperform vote while only 51.61% of users gave Opthea an outperform vote. CompanyUnderperformOutperformOptheaOutperform Votes1651.61% Underperform Votes1548.39% Kura OncologyOutperform Votes42569.56% Underperform Votes18630.44% SummaryOpthea and Kura Oncology tied by winning 7 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$195.04M$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E RatioN/A46.24135.1817.53Price / Sales1,529.36440.311,235.42140.39Price / CashN/A182.1340.6537.95Price / Book-2.513.924.884.92Net Income-$220.24M-$42.03M$118.97M$225.78M7 Day Performance-6.45%-3.37%16.19%-1.58%1 Month Performance-1.06%7.95%16.02%6.67%1 Year Performance27.04%21.00%34.95%22.48% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea2.2663 of 5 stars$3.22-1.5%$12.00+272.7%+29.8%$188.03M$124,666.000.008News CoveragePositive NewsGap DownKURAKura Oncology4.529 of 5 stars$9.98+3.6%$29.38+194.3%-20.8%$776.05MN/A-4.08142IMNMImmunome2.6346 of 5 stars$12.32-2.1%$28.83+134.0%+59.4%$768.98M$10.13M-1.5540Short Interest ↓Positive NewsTYRATyra Biosciences2.1888 of 5 stars$15.06+0.8%$31.00+105.8%+12.7%$762.04MN/A-9.2820ERASErasca2.6129 of 5 stars$2.62+2.3%$5.90+125.2%+40.6%$740.75MN/A-3.08126Positive NewsGap UpCRONCronos Group2.3543 of 5 stars$1.92-0.3%$3.00+55.9%+1.0%$735.85M$87.24M-15.19356Short Interest ↓News CoveragePositive NewsEOLSEvolus3.9289 of 5 stars$11.50-0.1%$23.00+100.0%+18.5%$728.18M$202.09M-12.73170Positive NewsDNTHDianthus Therapeutics1.6778 of 5 stars$24.02+0.9%$46.43+93.3%+235.7%$710.99M$2.83M-9.5280Positive NewsRAPPRapport Therapeutics1.8607 of 5 stars$18.92+0.8%$35.00+85.0%N/A$692.09MN/A0.00N/APositive NewsOCSOculis1.8181 of 5 stars$17.05-0.2%$29.20+71.3%+74.5%$690.59M$980,000.00-8.852AUTLAutolus Therapeutics3.0234 of 5 stars$2.58+3.6%$10.40+303.1%-50.3%$686.51M$1.70M-2.19330 Related Companies and Tools Related Companies KURA Alternatives IMNM Alternatives TYRA Alternatives ERAS Alternatives CRON Alternatives EOLS Alternatives DNTH Alternatives RAPP Alternatives OCS Alternatives AUTL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OPT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectCrypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPT Stock Alerts